« Back
Home /
Atorvastatin

Atorvastatin

Item no.	HY-B0589-1ea
Manufacturer	MedChem Express
CASRN	134523-00-5
Amount	1 ea
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 200 mg 500 mg 50 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.64
Citations	[1]Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82.\|[2]Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22.\|[3]Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61.\|[4]Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72.\|[5] Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821.\|[6]Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415. Acta Diabetol. 2025 Mar 27. Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. Biomed Pharmacother. 2023 Oct:166:115323. Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. Cancer Lett. 2023 Jan 1:552:215976. Cell Cycle. 2019 Dec;18(23):3337-3350. Cell Cycle. 2021 Oct;20(20):2160-2173. Chem Biol Interact. 2025 Oct 22:420:111671. Clin Pharmacol Ther. 2025 Jul 14. Emerg Microbes Infect. 2025 Dec;14(1):2470371. Endocrinology. 2022 Jul 1;163(7):bqac076. Environ Sci Technol Lett. 2025 Apr 8. Eur J Pharmacol. 2023 Oct 5:956:175938. Eur J Pharmacol. 2024 Feb 5:964:176261. Eur J Pharmacol. 2025 Feb 5:177357. Exp Cell Res. 2023 Dec 15;433(2):113829. Exp Neurol. 2025 May 16:115305. FEBS Open Bio. 2025 Aug 8. Front Cell Dev Biol. 2022 Mar 3;10:806081. Front Pharmacol. 2025 Apr 30:16:1573032. Inflammation. 2024 Oct 31. Int Immunopharmacol. 2025 Dec 3:166:115644. Int J Mol Sci. 2023 Apr 19;24(8):7492. J Appl Toxicol. 2024 Apr 19 J Appl Toxicol. 2024 Aug;44(8):1198-1213. J Mol Neurosci. 2022 Mar;72(3):565-573. J Nat Prod. 2022 Jul 22;85(7):1738-1750. J Neuroimmunol. 2020 Oct 24:350:577429. J Tradit Complement Med. 2024 Mar 29. Life Sci. 2025 Jun 1:370:123571. Med Gas Res. 2025 Mar 1;15(1):148-155. MedComm (2020). 2024 Aug 31;5(9):e681. Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. Nat Aging. 2025 Aug 26. Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3659-3670. Oncogene. 2022 Dec;41(49):5266-5278. Oncologie. 2025 May 26. Orebro University. 2024. Phytomedicine. 2023 Jul 26;119:154997. Phytomedicine. 2025 Jul:142:156713. Phytomedicine. 2025 Oct:146:157128. Proteomics. 2023 Aug;23(16):e2300041. Research Square Preprint. 2021 Dec. Research Square Preprint. 2022 Jun. Research Square Preprint. 2024 Apr 9. Sci Rep. 2020 Jan 28;10(1):1308. Signal Transduct Target Ther. 2023 Dec 25;8(1):457. Signal Transduct Target Ther. 2025 Nov 12;10(1):366. SSRN. 2025 Apr 9. Adv Sci (Weinh). 2024 Jul 5:e2403451. Arch Biochem Biophys. 2025 Jan 21:765:110316. bioRxiv. 2024 Jul 3:2024.07.01.601474. Cell Death Dis. 2021 May 13;12(5):482. Endocrinology. 2018 May 1;159(5):2008-2021. Free Radic Biol Med. 2024 Aug 1:220:179-191. Front Bioeng Biotechnol. 2022 Mar 17;10:826093. Nat Metab. 2025 Sep 22. Pharmaceutics. 2022 Jan 12;14(1):176. Eur J Med Chem. 2024 Dec 5:279:116842.
Smiles	O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Autophagy; HMG-CoA Reductase (HMGCR)
Manufacturer - HS Code	H302, H315, H319, H335
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	558.64
Product Description	Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively[1][2][3].
Manufacturer - Research Area	Metabolic Disease; Inflammation/Immunology; Cancer
Solubility	DMSO : ≥ 100 mg/mL
Manufacturer - Pathway	Autophagy; Metabolic Enzyme/Protease
Clinical information	Launched
UNSPSC Code	12352005
Precautionary	H302, H315, H319, H335

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.